Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.77 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.77 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.77 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | DPP4 | P27487 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.77 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.77 |
| ▸ | GAPDH | P04406 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | PI4KA | P42356 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.77 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.77 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.77 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL3183004 | 1.00 | ADORA1 (0.77) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL7516483 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3134331 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL926532 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3343948 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL924728 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL925631 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3166848 | 0.99 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3332132 | 0.98 | ADORA1 (0.74) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL10396858 | 0.98 | ADORA1 (0.74) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | claimed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | claimed |
| CN-111041067-A | Reagent and method for detecting β -lactamase and inhibiting drug resistance of compound agent thereof | 赛莱克斯(深圳)科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-20020168328-A1 | Cell photoprotective complex anti-pollution agent | L'OREAL (FR) | 2002-11-14 | — | — | US | claimed |
| CN-121242142-A | Feed additive for preventing and improving low-phosphorus leg disease of poultry and preparation method and application thereof | 扬州大学 | 2026-01-02 | — | — | CN | disclosed |
| CN-120754015-A | Scalp care composition and preparation method thereof | 北京圣美细胞生命科学工程研究院有限公司 | 2025-10-10 | — | — | CN | disclosed |
| EP-4570798-A1 | AROMATIC HETEROCYCLIC CYCLOHEXYL AMINOALKYL PIPERIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-118562917-A | Method for biosynthesis of guanosine diphosphate by multienzyme method | 汇海(苏州)生物技术有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-117624263-A | Preparation method and application of disodium adenosine triphosphate crystal | 安徽翠鸟生物技术有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| US-11634545-B2 | Layered-substance-containing solution and method of manufacturing same | ADEKA CORPORATION (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20020168328-A1 | Cell photoprotective complex anti-pollution agent | L'OREAL (FR) | 2002-11-14 | — | — | US | disclosed |
| EP-0652285-B1 | Lactic acid bacteria and fermented milk product | CALPIS CO LTD (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1208755-A1 | COMPOSITIONS FOR FOODS, PROCESS FOR PRODUCING THE SAME AND FUNCTIONAL FOODS AND DRINKS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-5695796-A | MUTANT LACTOBACILLUS LACTIC ACID BACTERIA | THE CALPIS FOOD INDUSTRY CO., LTD. (JP) | 1997-12-09 | — | — | US | disclosed |
| US-5541111-A | Lactobacillus helveticus mutants having low increase in acidity of lactic acid during storage | THE CALPIS FOOD INDUSTRY CO., LTD. (JP) | 1996-07-30 | — | — | US | disclosed |
| EP-0652285-A2 | Lactic acid bacteria and fermented milk product | The Calpis Food Industry Co., Ltd. (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-4164571-A | Medicament which antagonizes the action of gastrin and related polypeptides | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1979-08-14 | — | — | US | disclosed |
| US-4046879-A | TOPICAL | BOEHRINGER INGELHEIM GMBH (DT) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | ADORA1 1178/4885ADORA3 1172/4885ADORA2A 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.